Notice of Proposed Sale · 144
AnaptysBio, Inc.
ANABNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- ANAPTYSBIO, INC.
- Issuer CIK
- 0001370053
- SEC file number
- 001-37985
- Phone
- (858) 362-6295
- Person for whose account securities are to be sold
- HOLLINGS C RENTON
- Relationships to issuer
- Director
- Street
- 10770 Wateridge Circle, Suite 210
- City
- San Diego
- State / country code
- CA
- Postal code
- 92121
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 5,000 | 249,371.50 | 29,895,244 | 10/01/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/01/2026 | Stock Option Exercise | Issuer | 5,000 | N | 10/01/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 10/01/2026
- Signed
- /s/ Hollings Renton
- Plan adoption dates
- 03/30/2026
Company context
Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www. AnaptysBio.com or follow us on LinkedIn.